Gene Expression Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037.
Storr Liver Centre, Westmead Institute for Medical Research and Sydney Medical School, University of Sydney, Westmead NSW 2145, Australia.
Proc Natl Acad Sci U S A. 2022 Dec 20;119(51):e2213041119. doi: 10.1073/pnas.2213041119. Epub 2022 Dec 12.
The pleiotropic actions of the Farnesoid X Receptor (FXR) are required for gut health, and reciprocally, reduced intestinal FXR signaling is seen in inflammatory bowel diseases (IBDs). Here, we show that activation of FXR selectively in the intestine is protective in inflammation-driven models of IBD. Prophylactic activation of FXR restored homeostatic levels of pro-inflammatory cytokines, most notably IL17. Importantly, these changes were attributed to FXR regulation of innate lymphoid cells (ILCs), with both the inflammation-driven increases in ILCs, and ILC3s in particular, and the induction of and in ILC3s blocked by FXR activation. Moreover, a population of ILC precursor-like cells increased with treatment, implicating FXR in the maturation/differentiation of ILC precursors. These findings identify FXR as an intrinsic regulator of intestinal ILCs and a potential therapeutic target in inflammatory intestinal diseases.
法尼醇 X 受体 (FXR) 的多效作用对于肠道健康是必需的,而反过来,在炎症性肠病 (IBD) 中则观察到肠道 FXR 信号转导减少。在这里,我们表明,FXR 在肠道中的选择性激活在 IBD 的炎症驱动模型中具有保护作用。FXR 的预防性激活恢复了促炎细胞因子的稳态水平,特别是 IL17。重要的是,这些变化归因于 FXR 对先天淋巴细胞 (ILCs) 的调节,包括 ILCs 的炎症驱动增加,特别是 ILC3s 的增加,以及 FXR 激活阻断了和 在 ILC3s 中的诱导。此外,随着治疗的进行,ILC 前体细胞样细胞的数量增加,这表明 FXR 参与了 ILC 前体细胞的成熟/分化。这些发现确定了 FXR 是肠道 ILC 的内在调节剂,也是炎症性肠道疾病的潜在治疗靶点。
Proc Natl Acad Sci U S A. 2022-12-20
Int J Mol Sci. 2021-7-16
Adv Exp Med Biol. 2022
Front Immunol. 2019-4-5
Curr Opin Gastroenterol. 2015-11
Int J Mol Med. 2025-9
World J Clin Oncol. 2025-4-24
Immunity. 2019-4-16